Myriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing
March 21 2016 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, and Access
Health
®, an educational program focused on health
and wellness, today announced that they will air an educational
program on hereditary cancer that will appear on Lifetime®. The
program, titled “Hereditary Cancer Risk Assessment and Testing: The
Answer Is in Your DNA,” will run on Wednesday, March 30, 2016 7:30
am (ET/PT) and again on Wednesday, April 6, 2016 7:30 am (ET/PT).
Individuals diagnosed with hereditary cancer syndromes such as
Lynch Syndrome and Hereditary Breast and Ovarian Cancer Syndrome
are at significantly higher risk of developing cancer than the
general population. In this special episode of Access Health,
viewers will hear from experts in the field of hereditary cancer,
including certified genetic counselor Marianne Lotito and Angelina
Jolie's breast surgeon, Dr. Kristi Funk.
With regard to the show, Dr. Kristi Funk, M.D., said, “I am
excited to be a part of this special episode of Access Health which
educates individuals on the importance of cancer family history and
the role genetic testing plays in understanding both individual
cancer risk and related medical management options.”
The program discusses the value of knowing personal and family
cancer history, follows the inspirational journeys of two families
affected by hereditary cancer and highlights how genetic testing
positively impacted their lives and that of their families. The
program also discusses hereditary cancer resources, including
Myriad’s Hereditary Cancer Quiz that helps individuals learn about
their hereditary cancer risk. This quiz is an online resource that
helps individuals evaluate their personal/family cancer history and
whether they may be candidates for genetic testing. It then
generates a family history overview that can be shared with
healthcare providers.
“We are very excited to support this Lifetime program, which is
a broad, powerful resource for people seeking answers on a
variety of important health questions related to genetic testing
and cancer,” said Bret Christensen, general manager, Preventive
Care, Myriad Genetic Laboratories. “Our goal is to educate the
public and to empower all Americans to live healthier lives. The
Hereditary Cancer Quiz is a quick way for people to determine if
they have any red flags for hereditary cancer.”
To take the Hereditary Cancer Quiz, please visit
https://www.hereditarycancerquiz.com/.
About Myriad GeneticsFor more than 25 years,
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad discovers
and commercializes molecular diagnostic tests that: determine the
risk of developing disease, accurately diagnose disease, assess the
risk of disease progression, and guide treatment decisions across
six major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare costs.
Myriad is focused on three strategic imperatives:
transitioning and expanding its hereditary cancer testing markets,
diversifying its product portfolio through the introduction of new
products and increasing the revenue contribution from international
markets. For more information on how Myriad is making a difference,
please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to information to be presented in the Access
Health program, titled “Hereditary Cancer Risk Assessment and
Testing: The Answer Is in Your DNA"; data on the causes and risks
associated with hereditary cancer syndromes; and the
Company's strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2015, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media Contact: Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact: Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024